Every time you eat a salty meal, your kidneys face a choice: retain that sodium or excrete it. The NEDD4L gene sits at the heart of this decision. It encodes NEDD4L (Neural Precursor Cell-Expressed Developmentally Downregulated 4-Like)¹¹ NEDD4L (Neural Precursor Cell-Expressed Developmentally Downregulated 4-Like)
an E3 ubiquitin ligase that tags ENaC sodium channels for destruction in the kidney's collecting duct cells. When NEDD4L works well, it constantly prunes excess ENaC from the cell surface, keeping sodium reabsorption — and blood pressure — in check. When NEDD4L function is reduced, ENaC accumulates at the membrane, sodium floods back into the bloodstream, and blood pressure climbs.

The Mechanism

The rs1008899 variant sits deep within intron 1 of NEDD4L on chromosome 18q21 — not a coding change, but a tag for underlying regulatory or isoform-switching differences in the gene. NEDD4L produces multiple protein isoforms depending on which exons are included during splicing. The key isoform distinction involves the C2 domain²² C2 domain
a calcium-dependent lipid-binding module that controls NEDD4L's subcellular targeting and interaction strength with ENaC.

NEDD4L exerts its blood pressure effect through a precisely regulated chain: it ubiquitinates the PY motif of ENaC's beta and gamma subunits, triggering endocytosis and lysosomal degradation of the channel. Less ENaC at the apical membrane of collecting duct cells means less sodium reabsorption and lower blood volume. The G allele at rs1008899, which is in strong LD with rs292449 (D′=0.908, r²=0.533) but independent of the rs4149601 splice-site variant (D′<0.3, r²<0.1), tags a haplotype state associated with reduced ENaC ubiquitination efficiency — not through the C2-domain splice mechanism, but through a distinct regulatory locus.

This pathway is also regulated by WNK1 kinase³³ regulated by WNK1 kinase
WNK1 phosphorylates NEDD4L, modulating its ability to ubiquitinate ENaC; variants in the ADD1-WNK1-NEDD4L axis interact to determine individual sodium sensitivity.

The Evidence

The clearest evidence comes from the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) trial⁴⁴ Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) trial
McDonough et al., J Hypertens 2013, which genotyped rs1008899 alongside three other NEDD4L variants in 767 hypertensive patients (465 white, 302 African-American). Among white patients treated with hydrochlorothiazide (HCTZ), rs1008899 showed significant associations with blood pressure response — with A-allele carriers achieving greater reductions in both systolic and diastolic blood pressure. Associations remained significant after adjusting for the independent rs4149601 signal, confirming rs1008899 captures independent variance in HCTZ response. No associations were detected in African-Americans or with atenolol treatment, underscoring the variant's specificity to thiazide-sensitive, sodium-channel-mediated pathways in European-ancestry populations.

Salt-sensitivity experiments in a Swedish crossover trial of 39 normotensive subjects⁵⁵ Swedish crossover trial of 39 normotensive subjects
Dahlberg et al., PLoS One 2007 demonstrated that NEDD4L GG homozygotes at rs4149601 (the functional splice variant in high LD with rs292449 but not rs1008899) showed a systolic blood pressure shift of 18 mmHg on high-salt versus low-salt diet, compared to only 6 mmHg in AA carriers (P=0.007). Plasma renin, a marker of sodium excess, was correspondingly suppressed. The G-allele landscape across NEDD4L consistently marks individuals who retain sodium less efficiently when salt intake rises.

Long-term cardiovascular consequences were established in the Malmö Diet and Cancer cohort (n=27,564)⁶⁶ Malmö Diet and Cancer cohort (n=27,564)
Dahlberg et al., J Hypertens 2014, where the NEDD4L salt-sensitivity genotype carried a cardiovascular disease hazard ratio of 1.13 (95% CI 1.02–1.25, P=0.018) and coronary event HR 1.20 (95% CI 1.06–1.37, P=0.005) independent of blood pressure at baseline — suggesting NEDD4L-mediated sodium dysregulation has effects beyond simple blood pressure elevation.

Practical Actions

For GG homozygotes, the most important implication is pharmacogenomic: the standard first-line antihypertensive thiazide diuretic (HCTZ) may not lower blood pressure as effectively as in A-allele carriers. If you have hypertension and carry the GG genotype, discussing alternative or add-on antihypertensives (ACE inhibitors, ARBs, or mineralocorticoid receptor antagonists like spironolactone) with your prescriber is clinically relevant. Sodium restriction is particularly important because your ENaC system is less effectively downregulated — the kidney is slower to excrete a sodium load.

Heterozygous AG carriers occupy an intermediate position: their HCTZ response is better than GG but less robust than AA homozygotes.

Interactions

rs1008899 is in strong LD with rs292449 (D′=0.908, r²=0.533), so these two variants largely track together. The related rs4149601 functional variant (which directly alters NEDD4L splicing and C2-domain inclusion) represents an independent, stronger signal. Individuals carrying risk haplotypes at both rs1008899/rs292449 AND rs4149601 may have compounded sodium retention.

Interaction studies with ADD1 (alpha-adducin, rs4961) and WNK1 show that the sodium-handling effect of NEDD4L variants is amplified when combined with sodium-retaining ADD1 variants — individuals carrying risk genotypes at multiple nodes of the ENaC-regulation axis have the highest salt sensitivity and the greatest pharmacogenomic response to sodium-targeted therapy.

Anti-Müllerian hormone (AMH) is a small protein secreted exclusively by the granulosa cells of growing ovarian follicles. Because it reflects the pool of actively developing follicles, circulating AMH levels serve as the most practical and cycle-stable biomarker of ovarian reserve¹¹ ovarian reserve
The remaining functional pool of oocytes — the eggs available for future ovulation. Ovarian reserve declines continuously and irreversibly with age; AMH is the earliest and most sensitive blood marker of that decline. Genetic variation explains a meaningful fraction of why two women of the same age can have AMH levels that differ by an order of magnitude. rs10093345 is among the variants contributing to that heritable spread.

The Mechanism

rs10093345 lies on chromosome 8 (8p11.23) in an intergenic region near the EIF4EBP1 gene²² EIF4EBP1 gene
Eukaryotic translation initiation factor 4E binding protein 1 — encodes 4E-BP1, a repressor protein that blocks the assembly of the cap-dependent translation initiation complex by binding eIF4E. 4E-BP1 is one of the principal downstream effectors of the mTORC1³³ mTORC1
mechanistic target of rapamycin complex 1 — a central integrator of nutrient, growth factor, and energy signals that controls whether cells are in an anabolic (building) or catabolic (breaking-down) state signaling axis: when mTORC1 is active, it phosphorylates and inactivates 4E-BP1, releasing eIF4E to drive cap-dependent protein synthesis. When mTORC1 is suppressed, 4E-BP1 acts as a brake on translation.

In the ovary, mTOR signaling plays a critical role in granulosa cell proliferation and follicular activation. Glycolysis-driven mTOR activation in granulosa cells is a key trigger for primordial follicle recruitment⁴⁴ Glycolysis-driven mTOR activation in granulosa cells is a key trigger for primordial follicle recruitment
Zhang et al. Cell Death & Disease, 2022 (PMID 35087042); dysregulation of this pathway can accelerate follicle depletion or impair granulosa cell function. Colocalization analysis in the Pujol-Gualdo 2024 GWAS confirmed that the rs10093345 signal colocalizes with an expression quantitative trait locus (eQTL) for EIF4EBP1 itself — meaning the risk allele likely alters EIF4EBP1 transcript levels in relevant tissues, subtly modifying translational output in granulosa cells and potentially the quantity or timing of AMH secretion. The exact regulatory mechanism (enhancer, promoter, or splicing effect) has not yet been resolved at the molecular level.

The Evidence

The rs10093345 association was identified in a genome-wide association meta-analysis of AMH in 9,668 pre-menopausal women (ages 15–48)⁵⁵ genome-wide association meta-analysis of AMH in 9,668 pre-menopausal women (ages 15–48)
Pujol-Gualdo et al. Human Reproduction, 2024. Combined data from the Northern Finland Birth Cohort 1966 (n = 2,619) with a prior AMH GWAS meta-analysis (n = 7,049). The EIF4EBP1 locus reached genome-wide significance (P = 1 × 10⁻⁹) with a beta of 0.08 AMH units per T allele (95% CI 0.06–0.10), meaning each T allele is associated with approximately 0.08 unit lower AMH on the scale used in the analysis. The locus was one of three novel discoveries in this study, alongside CHEK2 and BMP4.

The effect is modest per allele — not large enough to determine AMH reserve on its own. Given the T allele frequency of approximately 73% in Europeans, the TT genotype is in fact the most common genotype in that population (~53% of individuals), meaning the "risk" genotype here describes the majority. Clinical AMH variability is dominated by age and individual biology; rs10093345 represents a small probabilistic shift in the distribution, rather than a deterministic outcome.

AMH peaks in the early 20s and declines progressively toward menopause⁶⁶ AMH peaks in the early 20s and declines progressively toward menopause
Dewailly et al. Human Reproduction Update, 2014 (PMID 24430863). Its correlation with antral follicle count makes it useful for individualized FSH dosing in IVF, for identifying women at risk of poor ovarian response, and for early detection of premature ovarian insufficiency (POI). In young women, very low AMH is a clinically meaningful signal for increased POI risk⁷⁷ very low AMH is a clinically meaningful signal for increased POI risk
Nelson et al. Climacteric, 2023 (PMID 36651193), and this genetic variant nudges baseline AMH in that direction — modestly and probabilistically, not absolutely.

Practical Actions

For TT homozygotes: the practical implication is awareness that your baseline AMH may trend slightly lower than the population average attributable to this locus — which is reason to consider an AMH measurement as part of any fertility evaluation, particularly before age 35 when reserve is still expected to be adequate and a documented baseline is most informative. For women considering delayed childbearing, knowing your AMH trend can inform the timing and urgency of fertility planning decisions, including whether egg freezing is worth discussing while reserve is still favorable.

For CT heterozygotes: the effect is approximately half that of TT homozygosity and is less clinically significant in isolation. An AMH test remains informative if fertility planning is actively relevant to you.

Interactions

This locus was identified in the same study that confirmed associations at MCM8 (rs16991615 — involved in DNA repair during follicular development), AMH itself (the gene encoding the hormone), and TEX41. Women carrying risk alleles at multiple AMH-influencing loci may have a compounded effect on circulating levels, though formal polygenic interaction analysis across these loci has not been published. The broader genetic architecture of ovarian reserve is emerging, with several GWAS loci converging on granulosa cell biology and follicular development pathways.

When a platelet is activated at a site of vascular injury, it releases a cascade of pro-aggregatory molecules from its internal storage granules — a process called degranulation¹¹ degranulation
the release of platelet granule contents (ADP, serotonin, thromboxane A2, fibrinogen) that amplifies the coagulation response and recruits additional platelets to the growing thrombus. The molecular machinery that executes this release depends on a family of vesicle-docking proteins called SNAREs. VAMP8 (vesicle-associated membrane protein 8, also known as endobrevin) is the key v-SNARE mediating fusion of dense granules and alpha-granules with the platelet plasma membrane. Without sufficient VAMP8, granule release is impaired; with excess VAMP8, platelets become hyperreactive. The rs1010 variant sits in the 3' untranslated region of VAMP8 mRNA and appears to modulate how much of this protein your platelets produce.

The Mechanism

The 3'UTR of a gene's mRNA transcript is the regulatory tail that controls message stability, localization, and translation efficiency — particularly through binding of small RNA molecules called microRNAs²² microRNAs
20–23 nucleotide RNA molecules that bind complementary sequences in the 3'UTR of target mRNAs and suppress translation or trigger degradation. Research by Kondkar et al. identified microRNA-96 (miR-96) as a regulator of VAMP8 expression: miR-96 caused dose-dependent decreases in both VAMP8 protein and mRNA in platelet-model cell lines. The rs1010 C allele falls within or near the miR-96 binding site in the 3'UTR, and is hypothesized to alter the efficiency of this miRNA-mediated suppression — allowing more VAMP8 mRNA to persist and more VAMP8 protein to accumulate in platelet precursor cells.

Higher VAMP8 protein translates to a lower threshold for degranulation: platelets with more VAMP8 release their contents more readily when stimulated by ADP, thrombin, collagen, or other agonists. Hyperreactive platelets — those with more pronounced degranulation — are an established intermediate phenotype on the causal pathway to arterial thrombosis.

Importantly, one study (Gaussem et al. 2009) found no association between rs1010 genotype and standard in vitro platelet function assays (aggregometry, flow cytometry for activation markers), suggesting the effect may be subtle, age-dependent, or context-specific rather than universally detectable under laboratory conditions.

The Evidence

The cardiovascular association evidence comes from several independent cohorts:

Shiffman et al.³³ Shiffman et al.
Association of gene variants with incident myocardial infarction in the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol, 2008 prospectively followed 4,522 adults aged ≥65 years and found the VAMP8 rs1010 C allele associated with incident MI at a hazard ratio of 1.2 (90% CI 1.02–1.41). This placed VAMP8 among the four SNPs with the strongest evidence for cardiovascular association in that panel.

Bare et al.⁴⁴ Bare et al.
Five common gene variants identify elevated genetic risk for coronary heart disease. Genet Med, 2007 included rs1010 in a composite five-variant cardiovascular risk score applied to 9,129 ARIC Study participants. Those in the top genetic risk tier (carrying 4–5 high-risk alleles including VAMP8 rs1010 C) had an HR of 1.57 (95% CI 1.21–2.04, P=0.001) for incident coronary heart disease versus the low-risk group.

Luke et al.⁵⁵ Luke et al.
Polymorphisms associated with noncardioembolic stroke and coronary heart disease. Cerebrovasc Dis, 2009 extended the finding to cerebrovascular events, reporting OR=1.21 (90% CI 0.99–1.49) for noncardioembolic stroke per C allele in the Vienna Stroke Registry — consistent in direction with the MI signal.

At the protein level, Kondkar et al.⁶⁶ Kondkar et al.
VAMP8/endobrevin is overexpressed in hyperreactive human platelets. J Thromb Haemost, 2010 found VAMP8 mRNA 4.8-fold higher in hyperreactive versus hyporeactive platelets (P=0.0023) across 288 healthy individuals, with protein levels varying 13-fold across subjects and 2.5-fold higher in the hyperreactive group (P=0.05). rs1010 was associated with platelet reactivity in an age-dependent manner (P<0.003). The Llobet et al. 2019⁷⁷ Llobet et al. 2019 thrombosis study reinforced the protein-level emphasis: elevated VAMP8 protein was associated with venous thrombosis in women (OR=3.25), but the rs1010 genotype itself showed no significant association — consistent with the variant acting as a partial modulator of expression rather than a deterministic switch.

The overall evidence level is moderate: replicated association with MI and stroke in multiple cohorts, plausible and partially characterized molecular mechanism, but contradictory in vitro platelet data and effect sizes in the HR=1.2 range that are modest and do not reach genome-wide significance thresholds.

Practical Actions

Carriers of one or two C alleles should be aware of their modestly elevated arterial thrombotic risk. Platelet hyperreactivity is a targetable intermediate phenotype: dietary long-chain omega-3 fatty acids (EPA and DHA) attenuate platelet activation and thromboxane A2 synthesis through mechanisms that are independent of VAMP8 but act on the same degranulation cascade. For CC homozygotes — who carry two copies of the high-expression allele — formal assessment of platelet function and overall cardiovascular risk profile is warranted when combined with other risk factors.

Antiplatelet therapy (aspirin, clopidogrel, ticagrelor) targets multiple steps in the platelet activation pathway including SNARE-mediated degranulation; whether rs1010 status predicts differential antiplatelet response is not yet established.

Interactions

VAMP8-mediated platelet hyperreactivity is one component of a larger thrombotic risk architecture. Variants in genes governing coagulation factor levels (F5, F2), fibrinolysis (SERPINE1/PAI-1), and platelet receptor function (ITGB3, GP1BA) can compound with VAMP8-driven hyperreactivity to substantially elevate arterial thrombotic risk beyond any single variant. The age-dependent association of rs1010 with platelet reactivity (Kondkar et al.) also suggests environmental or hormonal modifiers — particularly estrogen, which modulates platelet activation — may influence how strongly this variant expresses its phenotype.

NRXN3 (Neurexin-3) is not a metabolic gene. It does not regulate insulin, store fat, or burn energy. It is a synaptic cell-adhesion molecule — one of a family of proteins that build and stabilize connections between neurons in the brain's reward and feeding circuits. Yet it was pulled out of genome-wide association studies as a genuine obesity risk locus, pointing to a fundamental truth: in many people, excess weight is a neurological problem before it is a metabolic one.

The Mechanism

Neurexins act as molecular bridges across synapses, binding neuroligins¹¹ neuroligins
Postsynaptic proteins that pair with neurexins to specify synapse type — excitatory (glutamatergic) or inhibitory (GABAergic) and dystroglycans²² dystroglycans
Extracellular matrix receptors at the synapse that stabilize the synaptic cleft on the postsynaptic side. Neurexin-3 specifically controls AMPA receptor³³ AMPA receptor
The ionotropic glutamate receptor responsible for fast excitatory neurotransmission; its strength determines how powerfully one neuron activates another strength at glutamatergic synapses, meaning it regulates how intensely reward signals propagate through circuits.

NRXN3 is expressed heavily in glutamatergic projections from the prefrontal cortex⁴⁴ prefrontal cortex
The brain region governing impulse control, decision-making, and behavioral inhibition to the nucleus accumbens⁵⁵ nucleus accumbens
The brain's primary reward hub — the target of dopamine released during pleasurable experiences including food, sex, and addictive substances and in GABAergic neurons within the striatum. These are precisely the circuits that determine whether a reward signal (the smell of food, the taste of sugar) generates a "stop — satisfied" response or a "keep going — I need more" response. Variants that alter NRXN3 expression shift this balance, reducing the brake on appetitive drive.

A striking 2024 animal study found that selectively deleting NRXN3 in CaMKIIα-expressing neurons⁶⁶ CaMKIIα-expressing neurons
Neurons expressing Calcium/calmodulin-dependent protein kinase II alpha, a marker of excitatory projection neurons in the PVN of the paraventricular nucleus (PVN) of the hypothalamus⁷⁷ paraventricular nucleus (PVN) of the hypothalamus
A hypothalamic region integrating autonomic and endocrine signals to regulate energy balance, stress, and circadian rhythms caused substantially greater body fat accumulation⁸⁸ substantially greater body fat accumulation
Mu et al. Neurexin-3 in the paraventricular nucleus of the hypothalamus regulates body weight and glucose homeostasis independently of food intake. Molecular Brain, 2024 and impaired glucose tolerance — remarkably, without changing food intake at all. This shows that NRXN3 in the hypothalamus governs energy partitioning (how calories are stored versus burned), not merely appetite. Reducing NRXN3 function biases metabolism toward fat storage and glucose intolerance through autonomic and neuroendocrine pathways independent of conscious hunger.

The Evidence

rs10150332 lies within an intron of NRXN3 on chromosome 14q31. It was first identified in a CHARGE consortium GWAS⁹⁹ CHARGE consortium GWAS
Heard-Costa et al. NRXN3 is a novel locus for waist circumference. PLoS Genetics, 2009 of 31,373 individuals as a novel waist circumference locus. The G allele of the tag SNP rs10146997 (in complete linkage disequilibrium with rs10150332) was associated with 0.65 cm greater waist circumference per allele (combined p = 5.3×10⁻⁸, n = 70,014) and an obesity odds ratio of 1.13 (95% CI 1.07–1.19).

The Speliotes 2010 GIANT consortium meta-analysis¹⁰¹⁰ GIANT consortium meta-analysis
Speliotes et al. Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nature Genetics, 2010 of 249,796 individuals confirmed rs10150332 directly in the BMI analysis, with the C allele associated with β = 0.13 kg/m² higher BMI (p = 3×10⁻¹¹). A 2024 electronic health record PheWAS in a diverse population found even stronger signals: the C allele associated with obesity (β = 0.052, p = 2×10⁻²²) and overweight (β = 0.049, p = 7×10⁻²¹).

The NRXN3 locus also shows strong association with obstructive sleep apnea¹¹¹¹ obstructive sleep apnea
A sleep disorder in which upper airway obstruction causes repeated breathing interruptions — strongly linked to central obesity (OR 1.031, p = 1×10⁻⁸), consistent with the downstream effects of abdominal fat accumulation that the C allele promotes.

One of the most clinically important findings is the addiction-obesity overlap¹²¹² addiction-obesity overlap
Hishimoto et al. Neurexin 3 polymorphisms are associated with alcohol dependence and altered expression of specific isoforms. Human Molecular Genetics, 2007: NRXN3 variants in the same gene region were independently linked to alcohol dependence (splice-site SNP rs8019381, OR 2.46, p = 0.0007). The broader NRXN3 haplotypes that alter expression of specific transmembrane isoforms predispose to vulnerability to multiple addictive substances. This makes rs10150332 one of a handful of genetic loci where obesity risk and substance dependence risk converge through shared reward circuitry.

The population frequency of the C allele shows extreme stratification: ~21% in Europeans and ~40% in Africans, but essentially absent in East Asian populations (<1%). This near-fixation of the T allele in East Asians is one of the most dramatic frequency differences among all known obesity loci.

Practical Implications

The key insight from the NRXN3 biology is that the drive behind overeating in C allele carriers operates through reward and impulse- control circuits — the same circuitry that underlies compulsive behavior in addiction. Standard appetite management strategies that work for hypothalamic hunger signals (protein satiety, calorie restriction) may be less effective in isolation. Strategies that specifically target reward-driven eating — eliminating highly palatable trigger foods, restructuring the food environment, and building alternative reward pathways — are more aligned with the genetic mechanism.

The 2024 hypothalamic finding — that Nrxn3 loss causes fat accumulation independently of food intake — also points to energy expenditure as a key target. If the PVN's autonomic output is less effective at directing calories toward thermogenesis, building non-exercise thermogenesis and cold exposure habits may help counter this deficit.

Interactions

The most clinically relevant interaction is with DRD2 rs1800497 (Taq1A) in the brain-mental-health category. Both NRXN3 and DRD2 act in the mesolimbic reward circuit: NRXN3 governs synaptic connectivity of reward circuits while DRD2 governs dopamine receptor density within them. Carriers of risk alleles at both loci — weaker reward-circuit synaptic architecture (NRXN3 C) plus lower dopamine receptor density (DRD2 A allele) — may experience markedly heightened vulnerability to reward-driven overeating and food addiction-like behavior. This combination warrants targeted food environment restructuring.

NRXN3 acts independently of FTO (rs9939609) and MC4R (rs17782313), which operate through hypothalamic appetite and melanocortin pathways rather than reward circuitry. Carriers of risk alleles at all three loci face additive genetic load for obesity through distinct mechanisms — hypothalamic leptin insensitivity (FTO), melanocortin signaling deficit (MC4R), and reward-circuit dysfunction (NRXN3) — each warranting its own management approach.

CHD7¹¹ CHD7
chromodomain helicase DNA binding protein 7, an ATP-dependent chromatin remodeler encoded at chromosome 8q12.2 is best known for its catastrophic role in CHARGE syndrome²² CHARGE syndrome
a rare developmental disorder causing Coloboma, Heart defects, Atresia choanae, Retarded growth, Genital abnormalities, and Ear anomalies — caused by heterozygous CHD7 loss-of-function mutations. Rare mutations eliminate CHD7 function; common intronic variants like rs1017861 operate more subtly — modulating how the gene is expressed during critical developmental windows.

CHD7 is an essential regulator of neural crest cells³³ neural crest cells
a migratory embryonic cell population that gives rise to the peripheral nervous system, craniofacial skeleton, cardiac outflow tract, thymus, parathyroid glands, and inner ear. The thymus — and therefore much of the adaptive immune system's T-cell repertoire — develops from neural crest-derived pharyngeal pouch tissue under CHD7 control. This dual role in skeletal patterning and immune-system organogenesis places CHD7 in the innate and developmental immunity category alongside other genes whose structural contributions to the immune system matter as much as their direct immunological signalling.

The Mechanism

Rs1017861 lies in intron 2 of CHD7 (NM_017780.4:c.-175+27072A>G, GRCh38 chr8:60,706,154). The intronic location suggests it acts as a regulatory variant — influencing CHD7 expression levels or splice-site usage in specific tissues during development — rather than altering the CHD7 protein sequence. Precise cis-eQTL data for rs1017861 have not been published, but the variant's location near exons 2-4, where disease-associated haplotypes cluster most strongly, places it within the same regulatory neighbourhood as the functional polymorphisms identified in the Gao 2007 fine-mapping study.

CHD7 remodels chromatin at enhancers active during paraxial mesoderm and neural crest differentiation. When CHD7 activity is perturbed — even subtly — the transcriptional programmes that pattern the axial skeleton, paraspinal musculature, inner ear, and thymus are altered. The result in common-variant carriers is not a structural birth defect but a quantitative shift in tissue patterning that, at the population level, predisposes to adolescent idiopathic scoliosis (AIS) and possibly to subtle immune-tissue variation.

The Evidence

The primary genetic association comes from Gao et al. 2007⁴⁴ Gao et al. 2007
CHD7 gene polymorphisms are associated with susceptibility to idiopathic scoliosis — Am J Hum Genet, a linkage and association study of 52 IS families that produced a multipoint LOD of 2.77 (p = 0.0028) for chromosome 8q12, with fine-mapping of 23 CHD7 SNPs identifying significant disease-associated haplotypes (p < 1×10⁻⁴) over exons 2-4. This was the first report naming CHD7 as an IS susceptibility gene.

Direct evidence for rs1017861 itself comes from Borysiak et al. 2020⁵⁵ Borysiak et al. 2020
CHD7 gene polymorphisms in female patients with idiopathic scoliosis — BMC Musculoskelet Disord, a Polish case-control study of 211 female AIS patients and 83 controls. The rs1017861 polymorphism showed statistically significant association with IS susceptibility (p < 0.01) and with curve severity and progression rate (p < 0.05). The authors conclude that CHD7 should be considered an IS-modifying factor.

Replication has been mixed. Tilley et al. 2013⁶⁶ Tilley et al. 2013 failed to replicate CHD7 association across 22 SNPs in 244 European-descent familial IS families (p > 0.01), highlighting that familial and sporadic IS may have different genetic architectures, and that replication across ethnicities and study designs is incomplete. A 2025 study (Dai et al., PMID 39206768) further found that rs1017861 does not significantly predict brace treatment outcome, suggesting the variant is relevant for susceptibility rather than disease course once AIS is established.

The evidence level for this variant is therefore moderate — statistically significant association in at least one case-control study with plausible biological mechanism, but inconsistent replication and absent population-level GWAS confirmation at genome-wide significance thresholds.

Practical Actions

The primary actionable consequence is heightened awareness of scoliosis risk during adolescent growth. AIS emerges during the pubertal growth spurt (ages 10-16), has a strong female predominance, and responds well to bracing when detected at curves of 20-40°. GG carriers, particularly adolescent girls, benefit most from systematic spinal assessment during this window.

CHD7's role in neural crest-derived immune tissue development — especially thymus organogenesis — also connects this variant to the innate-infection category. Carriers with a history of recurrent infections, unusual immune responses, or sensorineural hearing loss may have a developmental basis worth investigating, though direct immunological evidence for rs1017861 specifically is not yet published.

Interactions

CHD7 at 8q12 sits alongside other AIS susceptibility loci identified in recent GWAS. The most studied co-loci include rs1978060 (TBX1, 22q11.21) and rs10738445 (BNC2). Combined burden across multiple AIS susceptibility variants predicts risk better than any single locus, though specific compound action data for the CHD7 + TBX1 or CHD7 + BNC2 combinations are not yet published. The developmental overlap between CHD7 and TBX1 — both are essential regulators of pharyngeal arch derivatives including the thymus, inner ear, and paraspinal tissues — makes a compound interaction biologically plausible.

STAT4 (Signal Transducer and Activator of Transcription 4) is a transcription factor that sits at the core of the IL-12 and interferon-alpha signaling cascade. When immune cells encounter pathogens or self-antigens, IL-12 and type I interferons activate JAK kinases, which phosphorylate STAT4, driving it into the nucleus where it triggers Th1 differentiation, NK cell activation, and IFN-gamma production¹¹ Th1 differentiation, NK cell activation, and IFN-gamma production
The STAT4 pathway is also the molecular target of JAK inhibitors used in rheumatoid arthritis and lupus treatment. rs10181656 lies in intron 3 of STAT4 and is the sentinel tagging SNP of the primary STAT4 risk haplotype for systemic lupus erythematosus — the variant that yielded the strongest statistical signal in a landmark Swedish fine-mapping study²² the strongest statistical signal in a landmark Swedish fine-mapping study
OR 1.71, 95% CI 1.40–2.08, P = 7.1 × 10⁻⁸; 485 SLE patients vs 563 controls.

The Mechanism

rs10181656 is in nearly perfect linkage disequilibrium with rs7574865 (r² ≈ 1.0), meaning both SNPs tag the same intron-3 haplotype block. The shared risk haplotype drives elevated STAT4 mRNA and protein expression³³ elevated STAT4 mRNA and protein expression
Risk haplotype cells produce significantly more STAT4 in mesenchymal tissues; overexpression correlates with anti-dsDNA antibody production, a hallmark of severe lupus. Carriers of the G risk allele therefore generate an amplified STAT4 response when type I interferons or IL-12 engage their T cells and NK cells — producing exaggerated IFN-gamma output and driving the "interferon signature" that characterizes active lupus in approximately 75% of SLE patients.

The specific value of rs10181656 as a distinct catalog entry is that it was the directly-genotyped sentinel in two studies with findings not captured elsewhere: the Swedish haplotype over-expression paper⁴⁴ Swedish haplotype over-expression paper
Study found this specific SNP pair, not rs7574865, represented all the observed association signal in their haplotype model and, more critically, the cerebrovascular risk study by Svenungsson et al.⁵⁵ cerebrovascular risk study by Svenungsson et al.
Two independent SLE cohorts, n=424 + 154; directly genotyped rs10181656(G) as the exposure variable.

The Evidence

The Löfgren et al. 2008 haplotype study⁶⁶ Löfgren et al. 2008 haplotype study
485 SLE patients, 563 controls; 53 STAT4 SNPs tested; rs10181656 and rs7582694 in perfect LD; OR 1.71 (1.40–2.08); P = 7.1×10⁻⁸; risk haplotype frequency 0.24 in cases vs 0.17 in controls identified rs10181656 as the strongest intra-locus signal from STAT4. Crucially, this risk haplotype was over-expressed in primary human mesenchymal cells and correlated with anti-dsDNA antibody production — establishing a molecular connection between the haplotype and lupus pathophysiology.

The most clinically striking finding comes from the Svenungsson et al. 2010 cerebrovascular study⁷⁷ Svenungsson et al. 2010 cerebrovascular study
Two SLE cohorts (n=424 and n=154); all Swedish; occurrence of ischemic cerebrovascular disease, ischemic heart disease, and venous thromboembolism documented; rs10181656(G) directly tested: G allele carriers with SLE had an OR of 2.3 (95% CI 1.6–3.3) for ischemic cerebrovascular disease — a magnitude "comparable to hypertension" as a stroke risk factor. The proposed mechanism runs through antiphospholipid antibody (aPL) accumulation: G allele carriers showed OR 1.6 (95% CI 1.2–2.0) for carrying two or more aPL types. Antiphospholipid antibodies promote platelet activation and thrombus formation in cerebral vessels, providing the mechanistic bridge from STAT4-amplified immune activation to stroke.

An independent Finnish SLE family cohort using transmission disequilibrium testing⁸⁸ Finnish SLE family cohort using transmission disequilibrium testing
TDT avoids population stratification artifacts; rs10181656 strongest intron-3 signal; p=0.001, OR 2.53 replicated the association. The intron-3 haplotype containing rs10181656 has also been associated with rheumatoid arthritis in Chinese Han and Korean cohorts⁹⁹ rheumatoid arthritis in Chinese Han and Korean cohorts
rs10181656 directly genotyped in Northwestern Chinese Han; also replicated in Korean RA cohorts, and with RA in an Iranian population (p=0.007), though notably the RA association does not replicate in African-Americans — consistent with a haplotype that is rarer in African-ancestry populations (~15% G allele frequency vs ~22% in Europeans).

Practical Actions

CG heterozygotes carry one copy of the STAT4 risk haplotype and face approximately 60–70% elevated SLE risk relative to CC homozygotes. Familiarizing yourself with lupus early warning signs and seeking prompt antinuclear antibody (ANA) testing if symptoms develop is appropriate monitoring given this background risk. GG homozygotes carry two copies of the risk haplotype, conferring more than doubled SLE risk (OR ~2.9 by dose-response extrapolation) and particularly elevated risk for the ischemic cerebrovascular complications documented in the Svenungsson study. For GG carriers, proactive baseline autoantibody testing and antiphospholipid antibody assessment provides important clinical context before symptoms emerge. If SLE is diagnosed in any G allele carrier, the STAT4-amplified JAK-STAT pathway (directly targeted by tofacitinib, baricitinib, and upadacitinib) may represent a particularly relevant therapeutic axis.

Interactions

rs10181656 and rs7574865 are in near-perfect linkage disequilibrium (r² ≈ 1.0) and tag the same STAT4 intron-3 risk haplotype. Users who have both SNPs genotyped will see consistent results across both entries — CG at rs10181656 corresponds to GT at rs7574865. The companion SNP rs10488631 (IRF5) operates upstream in the interferon production pathway, and its risk allele acts additively with the STAT4 haplotype to amplify total SLE susceptibility. CFB rs1270942 participates in the same lupus genetic architecture through the alternative complement pathway and further stratifies renal involvement risk. A compound action covering the combined STAT4 + IRF5 risk burden is proposed below (interaction candidate).

The timing of menopause is one of the strongest proxies for the size and health of the ovarian reserve — the pool of follicles a woman is born with and slowly depletes across her reproductive life. Women who reach menopause earlier tend to have lower anti-Müllerian hormone (AMH)¹¹ anti-Müllerian hormone (AMH)
the granulosa-cell glycoprotein that serves as the best single blood marker of how many follicles remain at every age, and a greater susceptibility to premature ovarian insufficiency (POI). Genome-wide association studies have repeatedly confirmed that DNA-damage-response genes cluster at the top of the list of genetic determinants of reproductive lifespan — and TLK1 is one of the clearest examples.

The Mechanism

TLK1 encodes a nuclear serine/threonine kinase whose activity is tightly coupled to active DNA replication, reaching peak levels during S phase. Its two best-characterised substrates are Asf1²² Asf1
anti-silencing function 1, a histone H3/H4 chaperone that is essential for nucleosome assembly onto newly synthesised and repaired DNA and RAD9, a scaffold protein in the DNA damage checkpoint. By phosphorylating Asf1, TLK1 ensures that chromatin is re-packaged efficiently behind the replication fork and at sites of double-strand break repair; by modulating RAD9, it controls how long the checkpoint remains active after damage is resolved.

The ovaries are extraordinarily dependent on accurate DNA repair. Primary oocytes are arrested in meiotic prophase I for decades — throughout which time they must faithfully maintain their genetic integrity against oxidative damage, metabolic stress, and the natural accumulation of replication errors from earlier development. Defects in homologous-recombination and chromatin-assembly genes are a well-established cause of accelerated follicle depletion³³ Defects in homologous-recombination and chromatin-assembly genes are a well-established cause of accelerated follicle depletion
See Ruth et al. 2021 (Nature) for a comprehensive map of DNA-repair loci governing ovarian ageing. The rs10183486 T allele at the TLK1 locus is intronic and does not change the TLK1 protein directly; its effect is likely mediated through altered splicing efficiency or regulatory element function that reduces TLK1 expression or activity in ovarian tissue.

The Evidence

The strongest evidence comes from a meta-analysis of 22 genome-wide association studies by Stolk et al. 2012⁴⁴ meta-analysis of 22 genome-wide association studies by Stolk et al. 2012
Meta-analyses identify 13 loci associated with age at menopause. Nature Genetics, 44:260–268, which examined 38,968 women of European descent and replicated findings in a further 14,435 women. The TLK1 locus reached genome-wide significance at P = 2.21×10⁻¹⁴, with each T allele associated with approximately 10 fewer weeks (beta = -0.196 years) before menopause onset. Among the 13 novel loci identified in that study, TLK1 was one of eight genes implicated in DNA-damage response and repair pathways — a striking enrichment that has been replicated in larger subsequent studies.

A cross-sectional cohort study of Iranian women by Mirinezhad et al. 2021⁵⁵ cross-sectional cohort study of Iranian women by Mirinezhad et al. 2021
Genetic Determinants of Premature Menopause in a Mashhad Population Cohort. Int J Fertil Steril, 2021 examined rs10183486 directly in 117 women with premature menopause and 183 controls. The T allele was more frequent in cases (36%) than controls (27%), with the TT homozygous genotype associated with an approximately 3.3-fold higher odds of premature menopause compared with CC homozygotes (OR 3.29, 95% CI 1.34–8.09, P = 0.010). A subsequent analysis from the same cohort found that rs10183486 genotype was also associated with altered hs-CRP levels, hinting at an inflammatory component in the TLK1–ovarian axis. Note that associations in the Mashhad cohort did not survive Bonferroni correction for multiple comparisons, reflecting the modest sample size; the primary evidence base remains the large European GWAS.

Population specificity is noteworthy: a replication study in Chinese women⁶⁶ replication study in Chinese women
Evaluating GWAS-Identified SNPs for Age at Natural Menopause among Chinese Women. PLoS ONE 2013 found that rs10183486 did not associate with menopause age in East Asian women (P = 0.325). This may reflect that rs10183486 is a tag SNP in high linkage disequilibrium with the true causal variant in Europeans (r² = 0.86 with rs4667673 in European panels) but not in East Asian populations (r² = 0.005), rather than a true null association.

Practical Actions

The clinical implication is modest but meaningful for reproductive planning. Each T allele may be associated with approximately 10 fewer weeks of reproductive lifespan; the TT genotype may be associated with up to 20 fewer weeks earlier menopause onset relative to CC individuals. For women planning families, this may translate into a somewhat earlier timeline for ovarian reserve monitoring.

Because the variant acts through a DNA-repair pathway, antioxidant support that protects oocytes from oxidative DNA damage is a plausible intervention — though direct evidence for supplementation reversing TLK1-pathway effects is not yet established. Reproductive endocrinologists increasingly use baseline AMH measurement in women with a family history of early menopause or who carry genetic risk variants at loci like TLK1 to guide family-planning timelines.

Interactions

The strongest documented interaction relevant to ovarian reserve is with rs16991615 (MCM8), another DNA-repair gene locus associated with early menopause and AMH levels in multiple cohorts. Both TLK1 and MCM8 operate in pathways required for accurate DNA replication and repair; women carrying T alleles at both loci may have additive reduction in reproductive lifespan, though a formal compound analysis of this pair has not been published. In the Stolk 2012 meta-analysis, the ovarian aging signal from DNA-repair loci (including TLK1, MCM8, HELQ, EXO1, FANCI, POLG, PRIM1) was collectively enriched beyond what individual loci would predict, suggesting these variants act partially through convergent pathways. See rs16991615 for the MCM8 profile.

The ST2 receptor encoded by IL1RL1 is the gateway through which IL-33¹¹ IL-33
Interleukin-33, a cytokine released by damaged airway and skin epithelial cells that acts as a danger signal for the type 2 immune system activates immune cells. When IL-33 docks onto ST2, the receptor's intracellular TIR domain²² TIR domain
Toll/IL-1 receptor homology domain — the intracellular signaling module that recruits adaptor proteins and fires downstream NF-kB and MAPK pathways relays the signal inside the cell. The rs10206753 missense variant sits directly in that TIR domain, changing amino acid 551 between leucine (Leu551, the risk haplotype) and serine (Ser551, the protective haplotype). This single amino acid difference meaningfully alters how hard the ST2 receptor fires when IL-33 arrives.

The Mechanism

rs10206753 is one of four coding changes that co-segregate in perfect linkage disequilibrium as a haplotype block in the IL1RL1 TIR domain. The risk haplotype (Ala433/Gln501/Thr549/Leu551, tagged by the T allele at rs10206753) produces a ST2 receptor that, when stimulated with IL-33, achieves a 2- to 3-fold induction of NF-kB signaling³³ 2- to 3-fold induction of NF-kB signaling
Measured in transfected cells stimulated with 10–50 ng/mL human recombinant IL-33; the protective Ser551 haplotype shows an attenuated response at equivalent stimulus concentrations. The protective haplotype (Thr433/Arg501/Ile549/Ser551, tagged by the C allele) shows a substantially attenuated signaling response to the same IL-33 stimulus. The Gln501Arg change within the haplotype is thought to be particularly important for this attenuated signaling, likely by altering adaptor protein recruitment to the TIR domain.

This is a distinct mechanism from the better-studied rs1420101 and rs11685480 eQTL variants, which affect how much sST2 decoy receptor is produced. rs10206753 instead changes the signal strength of the membrane-bound ST2L receptor itself — affecting IL-33 sensitivity at the receptor level rather than through decoy availability.

The Evidence

The IL1RL1 locus is among the most replicated asthma susceptibility loci in human genetics⁴⁴ IL1RL1 locus is among the most replicated asthma susceptibility loci in human genetics
Moffatt et al. NEJM 2010, GABRIEL GWAS of 10,365 cases and 16,110 controls across 10 populations; IL1RL1/IL18R1 locus p=3×10⁻⁹ for asthma. The TIR domain haplotype tagged by rs10206753 was functionally characterized by Portelli et al. JCI Insight 2020⁵⁵ Portelli et al. JCI Insight 2020
Phenotypic and functional translation of IL1RL1 locus polymorphisms in lung tissue and asthmatic airway epithelium, which showed that the risk haplotype ST2 protein produces significantly more NF-kB signaling per unit of IL-33 than the protective haplotype, while both haplotypes retain equivalent TNF-α responsiveness (confirming the effect is IL-33 pathway-specific).

Population evidence confirms the protective effect of the C allele. Bloodworth et al. JACI 2018⁶⁶ Bloodworth et al. JACI 2018
Association of ST2 polymorphisms with atopy, asthma, and leukemia reported an OR of 0.876 for asthma per C allele in a PheWAS of five ST2 SNPs including rs10206753, confirming the inverse relationship with asthma risk. The same study confirmed perfect linkage (r²=1) between rs10206753 and three other TIR domain coding variants (rs10192036, rs4988956, rs10192157), establishing that this is a haplotype effect rather than a single-SNP effect.

The C allele (protective Ser551 haplotype) appears protective against both asthma and chronic rhinosinusitis⁷⁷ chronic rhinosinusitis
Inflammation of the nasal sinuses persisting more than 12 weeks, frequently driven by the same IL-33/type-2 pathway as asthma. The same haplotype has been reported to modestly increase obesity risk, consistent with the role of IL-33/ST2 signaling in adipose tissue inflammation.

Practical Actions

For TT homozygotes — who carry two copies of the Leu551 risk haplotype and represent the most common genotype globally (~37% of Europeans) — the ST2 receptor is more reactive to IL-33. This means that when airway epithelium is damaged by allergens, viruses, or pollutants, IL-33 signaling reaches immune cells with greater intensity. The clinical translation is modestly elevated susceptibility to asthma and atopic disease, with the strongest actionability for those who already have asthma symptoms.

Given that rs10206753 and rs1420101 tag distinct mechanisms at the same gene, carriers of risk alleles at both loci may have synergistically elevated type-2-high asthma susceptibility: more reactive ST2 signaling (this variant) compounded with less sST2 decoy buffering (rs1420101 T allele).

Interactions

rs10206753 tags a haplotype that is independent of the primary sST2 eQTL signals (rs1420101 and rs11685480). Both mechanisms — receptor signaling amplitude (this variant) and decoy receptor availability (rs1420101 / rs11685480) — converge on the same IL-33/ST2 pathway. Carriers of risk genotypes at both loci face compounding effects: less IL-33 interception by circulating sST2 AND more IL-33-driven NF-kB activation once IL-33 reaches the membrane receptor.

Upstream IL33 variants (rs992969, rs1929992) further modulate the amount of IL-33 ligand produced by stressed epithelium. The full IL-33 axis risk can be assessed by genotyping the ligand (IL33), the decoy receptor (IL1RL1 eQTL signals), and the membrane receptor signaling amplitude (this TIR domain haplotype).

CCL2, also known as monocyte chemoattractant protein-1 (MCP-1), is the body's primary signal for drawing monocytes out of the bloodstream and into tissues. In healthy arteries, this recruitment is carefully controlled. In damaged or inflamed arteries, CCL2 expression surges, pulling monocytes into the arterial wall where they transform into foam cells — the lipid-laden macrophages that form the core of atherosclerotic plaques. The rs1024611 variant sits 2,518 base pairs upstream of the CCL2 coding sequence, directly in the gene's promoter region, where it acts as a molecular dial that turns up the volume on monocyte recruitment.

The Mechanism

The -2518 position in the CCL2 promoter overlaps a region that binds transcription factors controlling inflammatory gene expression. The G allele alters the binding affinity at this site, increasing basal and stimulated CCL2 transcription compared to the A allele. Functional studies in monocytes and endothelial cells show that G-allele constructs drive higher reporter gene activity than A-allele constructs under both resting conditions and inflammatory stimulation. The result is more circulating MCP-1 protein and a lower threshold for monocyte trafficking into inflamed tissues — including atherosclerosis-prone arterial segments at branch points and curvatures.

This mechanism is relevant beyond atherosclerosis. Elevated CCL2 drives monocyte infiltration in tuberculosis granulomas, HIV-associated vascular disease, and solid tumors. The -2518G allele consistently maps to conditions where monocyte overrecruitment is part of the pathology.

The Evidence

The most comprehensive cardiovascular data comes from a 2011 meta-analysis by Wang et al. — 24 studies, 9,844 CAD patients and 11,821 controls¹¹ Wang et al. — 24 studies, 9,844 CAD patients and 11,821 controls
Wang Y et al. Genetic variants of the monocyte chemoattractant protein-1 gene and its receptor CCR2 and risk of coronary artery disease: a meta-analysis. Atherosclerosis. 2011;219(1):224-30. Under the recessive model, GG homozygotes showed OR 1.42 (95% CI 1.06-1.92) for CAD in Caucasians. However, when restricted to studies with 500 or more participants, the effect dropped to OR 1.08 (95% CI 0.85-1.37) — no longer significant. The authors flagged probable publication bias among smaller studies.

The earliest and most cited positive study is Szalai et al. 2001 — 638 participants (318 CAD surgery patients, 320 controls)²² Szalai et al. 2001 — 638 participants (318 CAD surgery patients, 320 controls)
Szalai C et al. Involvement of polymorphisms in the chemokine system in the susceptibility for coronary artery disease. Atherosclerosis. 2001;158(1):233-9. GG homozygotes were 2.2 times more likely to have severe CAD requiring bypass surgery (95% CI 1.25-3.92, p<0.005), and they also showed significantly higher lipoprotein(a) levels — a compounding cardiovascular risk factor.

Blood pressure is another downstream effect. Penz et al. 2010 — 66 asymptomatic ischemic heart disease patients³³ Penz et al. 2010 — 66 asymptomatic ischemic heart disease patients
Penz P et al. MCP-1 -2518 A/G gene polymorphism is associated with blood pressure in ischemic heart disease asymptomatic subjects. Bratisl Lek Listy. 2010;111(8):420-5 found that G-allele carriers (AG + GG) had significantly higher systolic (p=0.037) and diastolic (p=0.021) blood pressure, and their calculated cardiovascular risk scores were nearly double those of AA carriers (3.17% vs 1.62%, p=0.004).

Not all studies agree. An Icelandic case-control study of 460 MI survivors and 1,842 controls found OR 0.87 (95% CI 0.71-1.08) — a null result in the opposite direction — illustrating the substantial heterogeneity across populations and study designs.

ClinVar classifies the G allele as a risk factor for coronary artery disease and as pathogenic for HIV-associated coronary artery disease, reflecting specific evidence that HIV amplifies the CCL2-driven vascular inflammation pathway beyond what occurs in HIV-negative individuals.

Practical Actions

For GG homozygotes, the evidence supports a focused cardiovascular surveillance strategy targeting the specific markers that this variant affects: monocyte-driven vascular inflammation and blood pressure. High-sensitivity CRP and lipoprotein(a) are particularly relevant — the Szalai 2001 study showed GG genotype paired with elevated Lp(a) created the highest CAD burden. Blood pressure monitoring is warranted because the Penz 2010 findings suggest the G allele's inflammatory effect manifests as measurable blood pressure elevation in established heart disease.

For AG heterozygotes, one G allele produces intermediate CCL2 expression — meaningfully above baseline but less than GG. Targeted monitoring of inflammatory cardiovascular markers is appropriate, especially in the presence of other risk factors.

Interactions

The CCL2 -2518G allele interacts with its receptor variant CCR2 rs1799864 (V64I). The CCR2 receptor is the primary target through which CCL2 recruits monocytes; variants in both the ligand (CCL2) and receptor (CCR2) can have additive effects on monocyte trafficking. The Wang 2011 meta-analysis analyzed both variants together, finding that CCR2 rs1799864 showed no independent CAD association in its own right, suggesting the ligand (CCL2) variant is the more functionally dominant of the two.

The rs1024611 G allele has also been studied in tuberculosis susceptibility and HIV-associated vascular disease — conditions where excess CCL2-mediated monocyte recruitment to infected or inflamed sites creates pathological tissue infiltration. These pleiotropic effects across diverse conditions reflect the centrality of CCL2 in monocyte biology.

The GLP-1 receptor (GLP1R) is the molecular target of semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), liraglutide (Saxenda), and other GLP-1 agonist medications prescribed for weight loss and type 2 diabetes. rs10305420 causes a proline-to-leucine substitution at position 7 of the receptor's signal peptide¹¹ signal peptide
a short amino acid sequence that directs newly synthesized proteins to the cell surface. Unlike other GLP1R pharmacogenomic variants that alter the drug-binding domain, this variant affects how efficiently the receptor reaches the cell membrane.

The Mechanism

The Pro7Leu substitution replaces proline — which introduces a structural kink — with leucine, a more hydrophobic amino acid that strengthens the signal peptide's hydrophobic core²² hydrophobic core
the water-repelling central region that is recognized by cellular machinery for membrane insertion. This is predicted to enhance signal recognition particle (SRP) binding³³ signal recognition particle (SRP) binding
the molecular complex that captures newly made proteins and directs them into the endoplasmic reticulum for processing and improve receptor trafficking to the plasma membrane. The result is more GLP-1 receptor molecules on the cell surface⁴⁴ more GLP-1 receptor molecules on the cell surface
Su et al. Genetic predictors of GLP1 receptor agonist weight loss and side effects. Nature, 2026, amplifying the cellular response to both natural GLP-1 and pharmaceutical agonists.

This mechanism explains a dual pharmacogenomic effect: more receptor on the cell surface means both greater drug efficacy (more weight loss) and greater susceptibility to GI side effects (more nausea and vomiting). Co-localization analysis in the Nature 2026 study confirmed that the efficacy, nausea, and vomiting signals at this locus share the same underlying causal variant.

The Evidence

The definitive evidence comes from a GWAS of 27,885 GLP-1 medication users⁵⁵ GWAS of 27,885 GLP-1 medication users
Su et al. Nature, 2026 conducted by the 23andMe Research Institute. The T allele (leucine) was associated with an additional 0.641% BMI loss per allele, equivalent to approximately 0.76 kg of extra weight loss per copy (P = 2.9 x 10^-10). The effect was additive with no evidence of dominance — two copies confer roughly twice the benefit. A trans-ancestry meta-analysis strengthened the signal further (P = 1.1 x 10^-12), with consistent directionality across European, Latino, African American, East Asian, South Asian, and Middle Eastern populations.

The association was independently replicated in 4,855 participants⁶⁶ independently replicated in 4,855 participants
All of Us Research Program cohort using EHR data with EHR-derived weight measurements (P = 0.001, effect = -0.47% BMI).

The same study identified an important gene-gene interaction with GIPR⁷⁷ gene-gene interaction with GIPR
rs1800437 Glu354Gln in near-perfect LD with rs10423928: individuals homozygous for risk alleles at both the GLP1R and GIPR loci had 14.8-fold increased odds of tirzepatide-induced vomiting (95% CI 6.2-35.8). This interaction was specific to tirzepatide, which targets both GLP1R and GIPR, and was absent in semaglutide-treated patients.

Two earlier, smaller studies reported opposite directionality — Jensterle et al. 2015⁸⁸ Jensterle et al. 2015 (n=57 PCOS women, liraglutide) and Yu et al. 2019⁹⁹ Yu et al. 2019 (n=285 Chinese T2D patients, exenatide) both found the T allele associated with less weight loss. These studies used different drugs, different populations, and had limited statistical power. The 23andMe study is approximately 100-fold larger and was independently replicated.

Practical Implications

This variant is common — approximately 48% of Europeans are heterozygous and 15% are homozygous for the T allele. Unlike rare pharmacogenomic variants, this affects a substantial fraction of GLP-1 medication users. The enhanced efficacy is clinically meaningful: homozygous TT carriers can expect roughly 1.5 kg more weight loss than CC carriers on the same regimen.

The trade-off is gastrointestinal tolerability. Carriers experiencing significant nausea or vomiting on GLP-1 agonists may benefit from slower dose titration. For tirzepatide users specifically, the interaction with GIPR variants can dramatically amplify vomiting risk — making GIPR genotype (rs10423928/rs1800437) clinically relevant information for prescribers choosing between semaglutide and tirzepatide.

Interactions

The GLP1R locus harbors multiple pharmacogenomic variants. rs6923761 (Gly168Ser) alters the extracellular binding domain, primarily affecting gastric emptying and glycemic response. rs3765467 (Arg131Gln) changes the ligand-binding pocket, modifying drug affinity. rs10305492 (Ala316Thr) affects intracellular signaling. Pro7Leu acts through a distinct mechanism — receptor trafficking rather than receptor function — and its effects are largely independent of these binding-site variants.

The tirzepatide-specific interaction with GIPR is unique to this variant among known GLP1R pharmacogenomic markers. The GIPR variant rs10423928 (in near-perfect LD with the coding variant rs1800437 Glu354Gln) reduces GIP receptor function. When combined with increased GLP1R surface expression from Pro7Leu, the balance between GLP-1 and GIP signaling is disrupted, unmasking the nausea-inducing effects of the GLP-1 component that GIP receptor activation normally buffers.